Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
Clinician,Inotuzumab,"Acute lymphoblastic leukaemia (ALL), bridge to transplant, relapsed/refractory CD22-positive, adults",Inotuzumab (Besponsa),Hospital,
